Amund相关文献与解析，生知库 | 链接生命科学的每一步

Zhu, Yiou; Ho, Quang Tri; Robinson, James P W; Kjellevold, Marian; Chang, Ruirong; Fuglebakk, Edvin; Ma, Jianmin; Song, Shijie; Dahl, Lisbeth; Nøstbakken, Ole Jakob; Markhus, Maria W; Nilsen, Bente M; Kögel, Tanja; Lundebye, Anne-Katrine; Azad, Atabak M; Uzomah, Abimbola; Kolding, Jeppe; Lien, Vidar S; Wiech, Martin; Zhang, Yanxu; Maage, Amund; Frøyland, Livar; Bank, Michael S

发表日期：2026

文献求助收藏

Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy

肠道菌群多样性可预测接受化疗和免疫治疗的转移性激素受体阳性乳腺癌患者的预后

期刊:Molecular Oncology

影响因子:4.5

doi:10.1002/1878-0261.70117

Ullern, Andreas; Holm, Kristian; Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Bang, Corinna; Naume, Bjørn; Hov, Johannes R; Kyte, Jon Amund

Individually tailored monitoring at home after hospitalization for HEART failure (IT-HEART): design and baseline characteristics of a randomized clinical trial

针对心力衰竭住院患者的个体化居家监测（IT-HEART）：一项随机临床试验的设计和基线特征

期刊:Heart Failure Reviews

影响因子:4.2

doi:10.1007/s10741-026-10635-1

Braanaas, Karoline S; Dammen, Toril; Fagerland, Morten W; Husebye, Einar; Leinaas, Amund; Schirmer, Henrik; Sverre, Elise; Aune, Erlend; Myhre, Peder L; Munkhaugen, John

Introducing needs-based epilepsy follow-up: Patient satisfaction compared to standard of care follow-up

引入基于需求的癫痫随访：患者满意度与标准护理随访的比较

期刊:Epileptic Disorders

影响因子:

doi:10.1002/epd2.70183

Birkeland, Isak; Dahl-Hansen, Eline; Syvertsen, Marte Roa; Kolstad, Eivind; Wollertsen, Yvonne Myrtvedt; Lillebø, Atle; Øvrebø, Solveig; Ese, Elin; Leinaas, Amund; Gilhus, Nils Erik; Bjørk, Marte Helene

Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival

转移性黑色素瘤患者接受伊匹木单抗治疗期间血浆蛋白动态变化：与肿瘤反应、不良事件和生存率的关系

期刊:Oncoimmunology

影响因子:6.3

doi:10.1080/2162402X.2024.2440967

Lereim, Ragnhild Reehorst; Dunn, Claire; Aamdal, Elin; Chauhan, Sudhir Kumar; Straume, Oddbjørn; Guren, Tormod Kyrre; Kyte, Jon Amund

Revisiting the Briggs Ancient DNA Damage Model: A Fast Maximum Likelihood Method to Estimate Post-Mortem Damage

重新审视布里格斯古代DNA损伤模型：一种快速最大似然法估算死后损伤。

期刊:Molecular Ecology Resources

影响因子:5.5

doi:10.1111/1755-0998.14029

Zhao, Lei; Henriksen, Rasmus Amund; Ramsøe, Abigail; Nielsen, Rasmus; Korneliussen, Thorfinn Sand

毒理研究

发表日期：2025

文献求助收藏

Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study

在一项 1 期研究中，健康受试者接受癌症候选疫苗 FMPV-1/GM-CSF 治疗后，体内产生了移码突变的 TGFβR2 特异性 T 细胞。

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s00262-025-03969-6

Inderberg, Else Marit; Singh, Nand; Miller, Robert; Arbe-Barnes, Sarah; Eriksen, Henrik K; Lversen, Berit; Juul, Hedvig Vidarsdotter; Eriksen, Jon Amund; Handeland, Karianne Risberg

Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer

肠道菌群多样性具有预后价值，并与转移性三阴性乳腺癌患者接受化疗-免疫疗法后的获益相关。

期刊:Molecular Oncology

影响因子:4.5

doi:10.1002/1878-0261.13760

Ullern, Andreas; Holm, Kristian; Røssevold, Andreas Hagen; Andresen, Nikolai Kragøe; Bang, Corinna; Lingjærde, Ole Christian; Naume, Bjørn; Hov, Johannes R; Kyte, Jon Amund

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials

接受免疫检查点抑制剂治疗的转移性乳腺癌患者循环肿瘤细胞——ALICE 和 ICON 试验的生物标志物分析

期刊:Molecular Oncology

影响因子:4.5

doi:10.1002/1878-0261.13675

Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Borgen, Elin; Schirmer, Cecilie Bendigtsen; Gilje, Bjørnar; Garred, Øystein; Lømo, Jon; Stensland, Marius; Nordgård, Oddmund; Falk, Ragnhild Sørum; Mathiesen, Randi R; Russnes, Hege G; Kyte, Jon Amund; Naume, Bjørn

A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

一项非随机、开放标签、探索性“机会窗口”研究，旨在评估TG02治疗局部晚期原发性和复发性RAS突变型结直肠癌患者的疗效。

期刊:Heliyon

影响因子:3.6

doi:10.1016/j.heliyon.2024.e41364

Roth, Sara; Wilson, Kasmira Claire; Ramsay, Robert George; Mitchell, Catherine; Sampurno, Shienny; Pham, Toan Duc; Huei Kong, Joseph Cherng; Wong, Stephen Q; Heriot, Alexander Graham; Deva, Sanjeev; Burge, Matthew; Sverdrup, Cecilie; Moller, Anne-Sophie; Kuryk, Lukasz; Eriksen, Jon Amund; Jaderberg, Magnus; Zalcberg, John Raymond; Michael, Michael

Global marine fish trade networks track international pathways of nutrients and contaminants

全球海洋鱼类贸易网络追踪营养物质和污染物的国际运输路径

Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy

肠道菌群多样性可预测接受化疗和免疫治疗的转移性激素受体阳性乳腺癌患者的预后

Individually tailored monitoring at home after hospitalization for HEART failure (IT-HEART): design and baseline characteristics of a randomized clinical trial

针对心力衰竭住院患者的个体化居家监测（IT-HEART）：一项随机临床试验的设计和基线特征

Introducing needs-based epilepsy follow-up: Patient satisfaction compared to standard of care follow-up

引入基于需求的癫痫随访：患者满意度与标准护理随访的比较

Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival

转移性黑色素瘤患者接受伊匹木单抗治疗期间血浆蛋白动态变化：与肿瘤反应、不良事件和生存率的关系

Revisiting the Briggs Ancient DNA Damage Model: A Fast Maximum Likelihood Method to Estimate Post-Mortem Damage

重新审视布里格斯古代DNA损伤模型：一种快速最大似然法估算死后损伤。

Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study

在一项 1 期研究中，健康受试者接受癌症候选疫苗 FMPV-1/GM-CSF 治疗后，体内产生了移码突变的 TGFβR2 特异性 T 细胞。

Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer

肠道菌群多样性具有预后价值，并与转移性三阴性乳腺癌患者接受化疗-免疫疗法后的获益相关。

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials

接受免疫检查点抑制剂治疗的转移性乳腺癌患者循环肿瘤细胞——ALICE 和 ICON 试验的生物标志物分析

A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

一项非随机、开放标签、探索性“机会窗口”研究，旨在评估TG02治疗局部晚期原发性和复发性RAS突变型结直肠癌患者的疗效。